| 01/07/11 |
Anchor Therapeutics Achieves Milestone in GPCR Collaboration |
| 12/08/10 |
Anchor Therapeutics Publishes Discovery of Novel Pepducin as Potent Agonist of Stem Cell Receptor |
| 09/15/10 |
Anchor Therapeutics Named a “Fierce 15” Biotech Company for 2010 |
| 09/09/10 |
Anchor Therapeutics Enters Into Collaborative Research, Option and License Agreement for its Pepducin Technology |
| 08/20/10 |
Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates |
| 07/21/10 |
Anchor Therapeutics Adds Global Experts to Board of Directors and Scientific Advisory Board |
| 03/30/10 |
Ascent Therapeutics Changes Name to Anchor Therapeutics |
| 12/21/09 |
Tufts Medical Center Receives Grant to Explore Pepducin Treatments for Acute Cardiovascular Indications |
| 09/10/09 |
Ascent Therapeutics Achieves Preclinical in vivo Proof-of-principle with Novel Pepducin™ GPCR Modulator Platform and Strengthens Senior Management Team |
| 06/02/09 |
Ascent Therapeutics Appoints Industry Leaders to Senior Management Team |
| 12/08/08 |
Ascent Therapeutics and Novartis Option Fund Enter into Licensing Option Agreement for Select Pepducin® Drug Candidates |
| 11/17/08 |
Ascent Therapeutics Debuts with the Appointment of CEO and Head of Discovery Research |
